ALAUNOS THERAPEUTICS, INC.

(TCRT)
  Report
Delayed Nasdaq  -  05/19 04:00:00 pm EDT
0.4816 USD   -0.54%
05/16TRANSCRIPT : Alaunos Therapeutics, Inc., Q1 2022 Earnings Call, May 16, 2022
CI
05/16ZIOPHARM : Q1 Earnings Snapshot
AQ
05/16ALAUNOS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/13/2022 05/16/2022 05/17/2022 05/18/2022 05/19/2022 Date
0.59(c) 0.5006(c) 0.5197(c) 0.4842(c) 0.4816(c) Last
2 498 068 1 837 333 1 654 634 1 518 254 1 278 926 Volume
+1.27% -15.15% +3.82% -6.83% -0.54% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -58,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,18x
Yield 2022 -
Sales 2023 - - -
Net income 2023 -70,8 M - -
Net Debt 2023 - - -
P/E ratio 2023 -1,88x
Yield 2023 -
Capitalization 104 M 104 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 41
Free-Float 89,6%
More Financials
Company
Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company. The Company is engaged in developing adoptive TCR engineered T-cell therapies (TCR-T), designed to treat multiple solid tumor types in large cancer patient populations. The Company is leveraging its cancer mutation hotspot TCR library and its non-viral Sleeping Beauty genetic engineering technology to design and manufacture... 
Sector
Biotechnology & Medical Research
Calendar
06/13 | 09:00amShareholder meeting
More about the company
Ratings of Alaunos Therapeutics, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about ALAUNOS THERAPEUTICS, INC.
05/16TRANSCRIPT : Alaunos Therapeutics, Inc., Q1 2022 Earnings Call, May 16, 2022
CI
05/16ZIOPHARM : Q1 Earnings Snapshot
AQ
05/16ALAUNOS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/16Alaunos Therapeutics Reports First Quarter 2022 Financial Results
AQ
05/16Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/16NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
05/10Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference
AQ
05/09Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022
AQ
05/04Wells Fargo Upgrades Alaunos Therapeutics to Overweight From Equalweight
MT
05/02ALAUNOS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (..
AQ
05/02Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annua..
AQ
05/02Alaunos Therapeutics Doses First Patient in Phase 1/2 Trial of TCR-T Cell Therapy in So..
MT
05/02ALAUNOS THERAPEUTICS : Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatm..
PU
05/02ALAUNOS THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/02Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treat..
AQ
More news
News in other languages on ALAUNOS THERAPEUTICS, INC.
05/16Alaunos Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 m..
05/02Alaunos Therapeutics administre la dose au premier patient de l'essai de phase 1/2 de l..
05/02Alaunos Therapeutics, Inc. administre la dose au premier patient de l'essai de phase 1/..
03/30Alaunos Therapeutics, Inc. annonce ses résultats pour l'année complète se terminant le ..
03/30Alaunos Therapeutics, Inc. annonce ses résultats pour le quatrième trimestre clos le 31..
More news
Analyst Recommendations on ALAUNOS THERAPEUTICS, INC.
More recommendations
Chart ALAUNOS THERAPEUTICS, INC.
Duration : Period :
Alaunos Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALAUNOS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 0,48 $
Average target price 4,30 $
Spread / Average Target 788%
EPS Revisions
Managers and Directors
Kevin S. Boyle Chief Executive Officer & Director
Timothy M. Cunningham Chief Financial Officer
Zuie Chin Huang Executive Chairman
Raffaele Baffa Chief Medical Officer & Executive VP-R&D
Drew Deniger Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ALAUNOS THERAPEUTICS, INC.-55.58%104
GILEAD SCIENCES, INC.-12.93%79 298
REGENERON PHARMACEUTICALS, INC.4.38%71 026
VERTEX PHARMACEUTICALS14.91%64 540
WUXI APPTEC CO., LTD.-18.77%41 409
BIONTECH SE-39.08%38 169